J Liver Cancer Search


J Liver Cancer > Volume 13(1); 2013 > Article
Journal of the Korean Liver Cancer Study Group 2013;13(1):74-79.
DOI: https://doi.org/10.17998/jlc.13.1.74    Published online February 28, 2013.
A Case of Recurred Hepatocellular Carcinoma after Treated by Trans-Arterial Chemoembolization
Sangheun Lee1, Mi Na Kim1, Young Eun Chon1, Beom Kyung Kim1, Seung Up Kim1,2,3,4, Jun Yong Park1,2,3,4, Do Young Kim1,2,3,4, Sang Hoon Ahn1,2,3,4,5, Chae Yoon Chon1,2,3,4, Kwang-Hyub Han1,2,3,4,5
1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
2Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea
3Liver Cancer Special Clinic, Yonsei University College of Medicine, Seoul, Korea
4Liver Cirrhosis Clinical Research Center, Seoul, Korea
5Brain Korea 21 Project for Medical Science, Seoul, Korea
Correspondence:  Kwang-Hyub Han,
Email: gihankhys@yuhs.ac
Hepatocelluar carcinoma (HCC) is the most common primary liver cancer in the world and the most prevalent cancer among patients liver cirrhosis. The management of HCC depends on tumor stage and the degree of liver dysfunction. Patients with intermediate-stage HCC are ineligible for surgical or local ablative treatments. Current treatment guidelines recommend trans-arterial chemoembolization (TACE) for intermediate stage of HCC. However, tumor recurrence after TACE is universal and the survival benefit is relatively small. Hence, new strategies are needed to improve the outcome of HCC patients undergoing TACE. Recently, the combination of target agents with TACE has shown promising overall survival in advanced HCC. It is necessary to investigate new treat strategy how to increase treatment outcome of advanced HCC by new treat strategy.
Key Words: Hepatocellular carcinoma; Trans-arterial chemoembolization; Brivanib

Editorial Office
1521 Gangnam Finance Plaza (FASTFIVE), 419 Teheran-ro, Gangnam-gu, Seoul 06160, Korea
Tel: +82-2-313-1900    E-mail: liver@klcsg.or.kr                

Copyright © 2022 by The Korean Liver Cancer Association.

Developed in M2PI

Close layer
prev next